This project will test the potential benefit of AZD0530 for Alzheimer’s disease modification. This is a phase 2a multicenter, randomized, double-blind, placebo-controlled study evaluating 18FDG-PET, safety, and tolerability of AZD0530 in 152 patients with mild AD.
|Effective start/end date||8/1/14 → 5/31/15|
- University of California, San Diego (67NWU/M15A11884)
- National Center for Advancing Translational Sciences (67NWU/M15A11884)